$NVO

$NVO Novo Nordisk: FDA Review of Denecimig BLA Extended Due to Manufacturing Facility Remediation ? • FDA has not identified deficiencies in submitted…

$NVO Novo Nordisk: Licenses Hengrui’s Oral GLP-1/GIP Drug HRS-1596 in Deal Worth Up to $2.6B ? • Novo will pay $300M upfront for exclusive rights outs…

$NVO is open to considering a direct NYSE listing, replacing the ADR structure U.S. investors use today. CEO told the FT a direct listing could help r…

$NVO Novo Nordisk LLY Eli Lilly: CagriSema Delivers Superior Weight Loss vs. Tirzepatide in REIMAGINE 5 ? • CagriSema patients lost 12.4% of body weig…

$NVO SAYS CAGRISEMA MET WEIGHT-LOSS SUPERIORITY IN PHASE 3 REDEFINE 9 TYPE 2 DIABETES AND OVERWEIGHT/OBESITY TRIAL…

$NVO investor meeting: Management says competition is at an unprecedented level for Novo, with “almost every other pharma company” targeting the obesi…

$NVO Novo Nordisk Capital Markets Day: CEO Says Wegovy Pill Has Reached 7M U.S. Prescriptions as Company Expands Beyond Obesity ? • CEO says the Wegov…

$NVO - NOVO: CHMP RECOMMENDS EU APPROVAL OF FREHEMGO® (DENECIMIG)…

$NVO Market sources: NOVO NORDISK will collaborate with ANTHROPIC to advance drug R&D…

$NVO Novo Nordisk: to Present 44 EASD Abstracts Sept. 28-Oct. 2 Across Wegovy, CagriSema and Next-Gen Amylin Pipeline ? • Novo will present new real-w…

$NVO d/g Underweight @ MS…

$NVO Novo Nordisk: STEP Young Phase 3 Meets Primary Endpoint as Two Heart-Disease Studies Are Halted ? • In STEP Young, 40.4% of children aged 6 to un…